Faith Charles Buys 7,100 Shares of CNS Pharmaceuticals (NASDAQ:CNSP) Stock

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Director Faith Charles acquired 7,100 shares of the business’s stock in a transaction on Monday, May 18th. The shares were purchased at an average price of $4.79 per share, for a total transaction of $34,009.00. Following the transaction, the director directly owned 7,100 shares of the company’s stock, valued at approximately $34,009. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

CNS Pharmaceuticals Stock Down 1.0%

CNSP stock opened at $5.05 on Friday. CNS Pharmaceuticals, Inc. has a twelve month low of $1.90 and a twelve month high of $14.76. The stock has a market capitalization of $4.09 million, a price-to-earnings ratio of -0.17 and a beta of 2.62. The firm’s fifty day simple moving average is $3.32 and its two-hundred day simple moving average is $4.82.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($7.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($8.82) by $1.52.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $20.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CNSP. Armistice Capital LLC bought a new position in shares of CNS Pharmaceuticals in the second quarter worth about $335,000. Ikarian Capital LLC bought a new position in shares of CNS Pharmaceuticals in the fourth quarter worth about $241,000. Finally, Boothbay Fund Management LLC bought a new position in shares of CNS Pharmaceuticals in the fourth quarter worth about $71,000. 14.02% of the stock is currently owned by institutional investors.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.